Univariate and multivariate Cox analysis was performed to evaluate the prognostic role of PKC genes in a pan-cancer analysis, and PKC isoenzymes were found to be solid biomarkers for the tumor immune status, with a distinctive PKC gene expression differently impacting the clinical outcome of cancer patients after immunotherapies. This evidence concerns the gene PRRT2 and neoplasm.